Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > CD20 > CD0-HP2E4

PE-Labeled Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (Site-specific conjugation)

Order Now

INTRODUCTION
QC & Assay Protocol
Citation & Background
  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    PE-Labeled Human CD20 Full Length Protein, His Tag (CD0-HP2E4) is produced via site-specific conjugation of PE to Human CD20 Full Length Protein, His Tag under optimal conditions with a proprietary technology. Human CD20 Full Length Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
    Predicted N-terminus: Met 1
    Request for sequence
  • Molecular Characterization
    CD20 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 36.9 kDa.

    Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by an amphipathic scaffold coat that confers enhanced stability and a narrow particle size distribution.

    The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein upon removal of the detergent.

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
*The isotype control of empty/mock nanodisc (Cat. No. APO-HP1E3) is sold separately and not included in protein, you can follow this link for product information.
Bioactivity-FACS
CD20 FACS

5e5 of Anti-CD20 CAR-293 cells were stained with 100 μL of 1:20 dilution (5 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HP2E4) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).​

Protocol
  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)
Show All Distributors
Bulk Inquiry Customize Product

Drug Candidate Licensing

more

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs：30 Details
  • Number of Drugs in Clinical Trials：96 Details
  • Latest Research Phase：Approved
More Recommended Products

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)
Show All Distributors

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
우리에게 전화하세요
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Email
이메일
order.kr@acrobiosystems.com
Fax
팩스
+1 888-377-6111
Address
주소
서울 성동구 왕십리로10길 6 서울숲비즈포레 703
회사명
아크로바이오 주식회사
사업자 등록번호
186-88-02858
대표자
CHEN YIDING
사업장주소
서울특별시 송파구 중대로12길 10-20, 1층 셀렉티드송파(가락동)
linkedin twitter facebook youtube

문의

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap